Total Payments
$685,123
2024 Payments
$74,041
Companies
44
Transactions
1,514
Medicare Patients
19,001
Medicare Billing
$1.6M
Payment Breakdown by Category
Other$566,600 (82.7%)
Travel$66,723 (9.7%)
Food & Beverage$28,837 (4.2%)
Consulting$22,156 (3.2%)
Education$807.61 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $566,340 | 262 | 82.7% |
| Travel and Lodging | $66,723 | 271 | 9.7% |
| Food and Beverage | $28,837 | 946 | 4.2% |
| Consulting Fee | $22,156 | 12 | 3.2% |
| Education | $807.61 | 21 | 0.1% |
| Honoraria | $260.08 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $210,403 | 305 | $0 (2024) |
| Lilly USA, LLC | $190,868 | 398 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $116,325 | 113 | $0 (2022) |
| PFIZER INC. | $54,753 | 101 | $0 (2024) |
| Janssen Biotech, Inc. | $41,064 | 100 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $23,954 | 48 | $0 (2024) |
| GENZYME CORPORATION | $13,969 | 24 | $0 (2024) |
| Galderma Laboratories, L.P. | $11,462 | 33 | $0 (2024) |
| UCB, Inc. | $8,528 | 46 | $0 (2024) |
| Amgen Inc. | $6,543 | 12 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $74,041 | 212 | ABBVIE INC. ($20,115) |
| 2023 | $71,628 | 161 | Lilly USA, LLC ($24,759) |
| 2022 | $133,621 | 273 | Lilly USA, LLC ($63,332) |
| 2021 | $53,644 | 144 | AbbVie Inc. ($27,569) |
| 2020 | $57,914 | 121 | Janssen Scientific Affairs, LLC ($25,968) |
| 2019 | $128,922 | 228 | AbbVie, Inc. ($68,045) |
| 2018 | $81,950 | 180 | Janssen Scientific Affairs, LLC ($20,957) |
| 2017 | $83,402 | 195 | AbbVie, Inc. ($25,875) |
All Payment Transactions
1,514 individual payment records from CMS Open Payments — Page 1 of 61
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.66 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $6.20 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $0.38 | General |
| Category: Immunology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $0.38 | General |
| Category: Immunology | ||||||
| 12/10/2024 | MAYNE PHARMA COMMERCIAL LLC | — | Food and Beverage | In-kind items and services | $6.17 | General |
| 12/09/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $11.03 | General |
| Category: Dermatology | ||||||
| 12/05/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $4.06 | General |
| Category: DERMATOLOGY | ||||||
| 12/04/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $676.79 | General |
| 12/04/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $146.78 | General |
| 12/04/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $146.58 | General |
| 12/04/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $22.19 | General |
| Category: Immunology | ||||||
| 12/04/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), BLU-U | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $7.06 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $6.94 | General |
| 12/04/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $2.08 | General |
| Category: DERMATOLOGY | ||||||
| 11/22/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: Dermatology | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.07 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $12.16 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Galderma Laboratories, L.P. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| 11/07/2024 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Inflammation & Immunology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $28.03 | General |
| Category: Immunology | ||||||
| 11/04/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $22.70 | General |
| Category: DERMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 4,785 | 10,582 | $2.2M | $424,401 |
| 2022 | 22 | 4,771 | 10,118 | $2.1M | $395,377 |
| 2021 | 25 | 4,730 | 9,961 | $2.0M | $403,340 |
| 2020 | 25 | 4,715 | 9,579 | $1.3M | $356,041 |
Total Patients
19,001
Total Services
40,240
Medicare Billing
$1.6M
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,049 | 1,734 | $514,998 | $98,477 | 19.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 384 | 702 | $394,524 | $81,488 | 20.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 510 | 644 | $243,432 | $49,025 | 20.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 760 | 996 | $222,108 | $32,838 | 14.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 343 | 422 | $142,636 | $25,920 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 197 | 274 | $115,080 | $23,259 | 20.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 647 | 4,837 | $111,251 | $21,850 | 19.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 268 | 268 | $98,892 | $17,326 | 17.5% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 50 | 53 | $67,575 | $16,246 | 24.0% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 50 | 52 | $48,516 | $10,281 | 21.2% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 52 | 57 | $33,858 | $6,694 | 19.8% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 31 | 31 | $31,341 | $6,215 | 19.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 143 | 163 | $30,429 | $5,742 | 18.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 49 | 49 | $26,803 | $4,937 | 18.4% |
| 17281 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 30 | 37 | $22,126 | $4,138 | 18.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 77 | 108 | $18,144 | $4,008 | 22.1% |
| 17272 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 24 | 24 | $15,048 | $3,199 | 21.3% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 23 | 23 | $21,321 | $2,346 | 11.0% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 14 | 16 | $10,928 | $2,319 | 21.2% |
| 69100 | Biopsy of ear | Office | 2023 | 33 | 37 | $11,877 | $2,035 | 17.1% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 12 | 13 | $10,569 | $1,959 | 18.5% |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | Office | 2023 | 11 | 13 | $8,333 | $1,652 | 19.8% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 17 | 18 | $8,856 | $1,486 | 16.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 11 | 11 | $4,609 | $960.61 | 20.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 1,135 | 1,833 | $540,735 | $103,870 | 19.2% |
About Dr. Thomas Hall, MD
Dr. Thomas Hall, MD is a Dermatology healthcare provider based in Stillwater, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174578280.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Hall, MD has received a total of $685,123 in payments from pharmaceutical and medical device companies, with $74,041 received in 2024. These payments were reported across 1,514 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($566,340).
As a Medicare-enrolled provider, Hall has provided services to 19,001 Medicare beneficiaries, totaling 40,240 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Stillwater, OK
- Active Since 05/24/2006
- Last Updated 12/13/2016
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174578280
Products in Payments
- TALTZ (Drug) $119,358
- TREMFYA (Drug) $96,688
- SKYRIZI (Biological) $67,540
- Humira (Biological) $58,271
- Tremfya (Drug) $38,826
- Olumiant (Drug) $33,594
- Skyrizi (Biological) $29,838
- EUCRISA (Drug) $27,006
- CIBINQO (Drug) $26,779
- RINVOQ (Biological) $26,680
- DUPIXENT DUPILUMAB INJECTION (Biological) $23,725
- OLUMIANT (Drug) $23,053
- STELARA (Biological) $21,819
- DUPIXENT (Drug) $8,503
- HUMIRA (Biological) $7,908
- ATOPIC DERMATITIS - DISEASE (Drug) $5,339
- Bimzelx (Biological) $3,982
- Enbrel (Biological) $2,468
- Otezla (Drug) $2,311
- ADBRY (Biological) $1,540
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.